NEW YORK (GenomeWeb) – The European Society for Medical Oncology Translational Research and Precision Medicine Working Group has developed a system for classifying molecular alterations found in patients’ tumors.
The system, described today in a publication in the Annals of Oncology, classifies alterations based on their relevance as markers for matching patients with targeted treatment, including both treatments that have regulatory approval and those that are still in clinical trials.
“For the first time, ESMO has created the tools to make it clear what data are needed for a mutation to be considered actionable and how this may change in response to new clinical data,” Joaquin Mateo, lead author of the paper and principal investigator of the Prostate Cancer Translational Research Group at the Vall d’Hebron Institute of Oncology in Spain, said in a statement. “The scale focuses on the clinical evidence for matching tumor mutations with the drugs we have in our clinics and gives us a common vocabulary for communication between clinicians, and for explaining potential treatment benefits to patients.”
In the study, the team described five classes of targetable mutations. Tier I mutations are targets that can be used in routine clinical decisions such as HER2 amplifications